Category: Type 2 Diabetes Mellitus

All Podcast Categories
S4-E48.1 - Reviewing TLM 2023 Part One: A Discussion With Zobair Younossi

S4-E48.1 – Reviewing TLM 2023 Part One: A Discussion With Zobair Younossi

Dr. Zobair Younossi joins Roger Green to kick off our review coverage of TLM 2023. Dr. Younossi discusses the studies he presented at the meeting and discusses other work related to patient quality-of-life, economics of screening and treatment, and how stigma affects both patients and providers.

S2-5 - Key Insights from the American Diabetes Association 83rd Scientific Sessions

S2-5 – Key Insights from the American Diabetes Association 83rd Scientific Sessions

Ken Cusi and Roger Green are joined by family practice researcher and KOL Eric Johnson and diabetologist and primary care KOL Jay Shubrook in a discussion around exciting news emerging from the ADA 83rd Scientific Sessions meeting. Layering in practical takeaways, the group explores their impressions from the meeting, the utility of FIB-4 as a frontline screening tool, guidelines and recommendations, therapeutic options both now and in the imminent future, and lastly the new nomenclature rollout for Fatty Liver disease.

S4-32 - Drug Development Stories from EASL and ADA: Part 1

S4-32 – Drug Development Stories from EASL and ADA: Part 1

Stephen Harrison and Jörn Schattenberg join Roger Green to discuss newly released Phase 3 MAESTRO-NASH data on resmetirom and the wider NASH therapeutic landscape, AI-assisted digital pathology, what the field understands about liver volume reduction, an increasing burden of cirrhosis and much more. This episode is packed with robust analysis and insights stemming from a busy past month at the EASL Congress and ADA Scientific Sessions meetings.

S4-31.4 - EASL Congress and ADA Scientific Sessions: Reshaping the way we think about Fatty Liver Disease

S4-31.4 – EASL Congress and ADA Scientific Sessions: Reshaping the way we think about Fatty Liver Disease

Roger Green is joined by Jörn Schattenberg to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This final conversation explores a range of topics including the role of artificial intelligence and general observations around how the different questions being asked in 2023 versus 2019 demonstrate dramatic changes in how the field understands Fatty Liver disease.

S4-31.1 - Mazen Noureddin on "NASH Monopoly"

S4-31.1 – Mazen Noureddin on “NASH Monopoly”

Roger Green is joined by KOL Mazen Noureddin to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This is the first conversation of a series of deep-dive episodes dedicated to unpacking the 2023 EASL Congress and the 83rd annual American Diabetes Association Scientific Sessions.

Sponsoring Partnerships!

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.